enfortumab vedotin + cisplatin

Enfortumab vedotin + cisplatin is a **drug combination** under investigation for the treatment of advanced urothelial carcinoma, specifically as a chemotherapy regimen for patients who are eligible for platinum-based therapies. **Enfortumab vedotin** is an antibody-drug conjugate targeting Nectin-4 (an adhesion protein highly expressed in urothelial cancers). It consists of a fully human monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Mechanistically, enfortumab vedotin binds Nectin-4–expressing tumor cells, is internalized, then releases MMAE intracellularly to disrupt the microtubule network, induce cell cycle arrest, and trigger apoptotic cell death[4][6]. **Cisplatin** is a platinum-based chemotherapeutic agent, working primarily by forming DNA crosslinks that inhibit DNA synthesis and function, leading to apoptotic cell death. Together, this combination brings both targeted cytotoxicity via enfortumab vedotin and broad cytotoxic effect via cisplatin. The regimen is studied for metastatic urothelial carcinoma, including in patients who may receive platinum chemotherapy (cisplatin-eligible), but does not yet have an approved brand name or readout distinct from individual drugs.